# OnCo record paper-zuma-2-brexu-cel-mantle-cell-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-zuma-2-brexu-cel-mantle-cell-nejm-2020" ;
  schema:name "ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors"@en ;
  schema:description "In mantle cell lymphoma that had stopped responding to BTK inhibitors, a single CAR-T infusion produced responses in 93% of patients and complete remissions in two-thirds."@en ;
  schema:url <https://onco.cc/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1914347>, <https://clinicaltrials.gov/study/NCT02601313> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1914347> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Wang M, Munoz J, Goy A, et al." ;
  onco:related <https://onco.cc/key-papers/paper-zuma-1-axi-cel-nejm-2017/> ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/pirtobrutinib/> ;
  onco:companies <https://onco.cc/companies/gilead/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/orr/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:journals <https://onco.cc/journals/nejm/> .